A Phase 1 interventional study of AV-380 and Placebo in Cachexia, sponsored by AVEO Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-12.
Sponsored by AVEO Pharmaceuticals, Inc. (part of LG Chem) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.
Among the 95 studies in Cachexia with a site in United States, this one is the 36th largest by enrollment of the 72 interventional ones that give a count, is one of 3 that started in 2021, is one of 21 in phase 1, and was the 76th registered.
331 studies on the registry are indexed under Cachexia; 74 are open to participants now.
Browse Cachexia studies →9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
CatalYm GmbH · Sites in United States, Bulgaria, Czechia and 11 more countries
Ages 18+
Pfizer · Sites in United States, Australia, Belgium and 18 more countries
Ages 18+
Endevica Bio · Sites in United States, Canada
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 26 · Phase 3 20 · Phase 4 2
First in 1997; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 74 across 226 interventional studies indexed under Cachexia.
Median enrollment 51 across the 72 interventional studies, 36 across the 16 observational. Of the 82 that completed or were terminated, 28 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 95 have an industry lead sponsor. The 10 most frequent:
This study is registered under AVEO Pharmaceuticals, Inc., one of the names counted as LG Chem. Under that name alone:
AVEO Pharmaceuticals, Inc. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.
LG Chem has 3 studies filed under Cachexia — fewer than ten, so there is no comparison to draw.
4 of the studies in Cachexia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06721260University of Kansas Medical CenterMetabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS) | 2027-01 |
| NCT07146893University of OklahomaFeasibility Study for Repurposing RET Inhibitors | 2027-02-23 |
| NCT05705492OHSU Knight Cancer InstituteOlanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | 2027-06-30 |
| NCT06937177Endevica BioSafely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 95 studies in Cachexia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This double-blinded, placebo-controlled, single ascending dose (SAD) study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity in healthy subjects of a single dose of AV-380. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
abnormalities in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IV infusion of AV-380 at dose level 4 mg/kg
Drug: AV-380
IV infusion of AV-380 at dose level 8 mg/kg
Drug: AV-380
IV infusion of AV-380 at dose level 13 mg/kg
Drug: AV-380
IV infusion of AV-380 at dose level 20 mg/kg
Drug: AV-380
Subcutaneous injection of AV-380 at dose level 4 mg/kg
Drug: AV-380
Subcutaneous injection of AV-380 at dose level 2 mg/kg
Drug: AV-380
Subcutaneous injection of AV-380 at dose level 1 mg/kg
Drug: AV-380
Drug: Placebo
AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Placebo is sterile liquid for IV infusion.
Assessment of adverse events (AEs) and treatment emergent adverse events (TEAEs)
Time frame: Through study completion, an average of 60 days
Injection site safety and tolerability assessment
Site injection tolerability will be assessed by the Investigator using a 4-level score (none, mild, moderate, severe) after IV infusion and SC injection.
Time frame: Visit Day 1
Clinical laboratory measurements - Hematology - hemoglobin
Hemoglobin (g/dL)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Hematology - hematocrit
Hematocrit (%)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Hematology - erythrocytes
Erythrocytes
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Hematology - white blood cell count
White blood cell count with differential (neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelets) (X10(3)/UL)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - sodium
Sodium (mmol/L)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - potassium
Potassium (mmol/L)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - calcium
Calcium (mg/dL)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - chloride
Chloride (mmol/L)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - CO2
CO2 (mmol/L)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - blood urea nitrogen
Blood urea nitrogen (mg/dl)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - creatinine
creatinine (mg/dL), glucose, total proteins, triglycerides, total cholesterol, AST, ALT, gamma-glutamyltransferase, creatinine phosphokinase, albumin, alkaline phosphatase, and total bilirubin
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - glucose
Glucose (mg/dL)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - total proteins
Total proteins (g/dL), triglycerides, total cholesterol, AST, ALT, gamma-glutamyltransferase, creatinine phosphokinase, albumin, alkaline phosphatase, and total bilirubin
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - triglycerides
Triglycerides (mg/dL)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - total cholesterol
Total cholesterol (mg/dL)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - AST
AST (U/L)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - ALT
ALT (U/L)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - Gamma-glutamyltransferase
Gamma-glutamyltransferase (U/L)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - Creatinine phosphokinase
Creatinine phosphokinase (mg/dL)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - albumin
Albumin (g/dL)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - alkaline phosphatase
Alkaline phosphatase (U/L)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Blood chemistry - total bilirubin
Total bilirubin (mg/dl)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Coagulation - partial thromboplastin time
Activated partial thromboplastin time (secs)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Coagulation - prothrombin time
Prothrombin time (sec)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Coagulation - International normalized ratio
International normalized ratio
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Hormonology
Measured parameters: Hormonology (TSH, FSH (for post-menopausal women); β-HCG (for women of childbearing potential))
Time frame: Visits Day 1 through Day 90
Clinical laboratory measurements - Hormonology - TSH
TSH (mIU/mL)
Time frame: Visits Day 1 through Day 90
Clinical laboratory measurements - Hormonology - FSH
FSH (mIU/mL)
Time frame: Visits Day 1 through Day 90
Clinical laboratory measurements - Urinalysis - pH
pH
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - protein
Protein (negative/positive)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - glucose
Glucose (negative/positive)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - leukocytes
Leukocytes (negative/positive)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - nitrites
Nitrites (negative/positive)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - ketones
Ketones (negative/positive)
Time frame: Visits Day 1 through Day 60
Clinical laboratory measurements - Urinalysis - blood
Blood (negative/positive)
Time frame: Visits Day 1 through Day 60
Vital signs measurements - Blood pressure
Supine and standing systolic and diastolic blood pressure (mmHg)
Time frame: Visits Day 1 through Day 90
Vital signs measurements - Heart rate
Heart rate (beats/min)
Time frame: Visits Day 1 through Day 90
Vital signs measurements - Body temperature
Body temperature (degrees Celsius)
Time frame: Visits Day 1 through Day 90
Vital signs measurements - Respiratory rate
Respiratory rate (breaths/min)
Time frame: Visits Day 1 through Day 90
Electrocardiogram (ECG) measurements - Mean heart rate
ECG mean heart rate (beats/min)
Time frame: Visits Day 1 through Day 90
Electrocardiogram (ECG) measurements - PR interval
PR interval, aggregate (msec)
Time frame: Visits Day 1 through Day 90
Electrocardiogram (ECG) measurements - QRS axis
QRS axis (deg)
Time frame: Visits Day 1 through Day 90
Electrocardiogram (ECG) measurements - QTcF interval
QTcF interval, aggregate (msec)
Time frame: Visits Day 1 through Day 90
Serum PK of single dose AV-380 via intravenous infusion and subcutaneous injection
Cmax (maximum observed serum concentration)
Time frame: Visits Day 1 through D90
Serum PK of single dose AV-380 via intravenous infusion and subcutaneous injection
Tmax (time to reach maximum serum concentration)
Time frame: Visits Day 1 through Day 90
To correlate the serum level of GDF-15 with the dose and serum level of AV-380
Emax (maximum effect observed)
Time frame: Visits Day 1 through Day 90
To correlate the serum level of GDF-15 with the dose and serum level of AV-380
AUEC (area under the effect-time curve)
Time frame: Visits Day 1 through Day 90
To correlate the serum level of GDF-15 with the dose and serum level of AV-380
TEmax (time to reach maximum effect)
Time frame: Visits Day 1 through Day 90
AV-380 immunogenicity in healthy subjects - anti-AV-380 antibodies (human anti-human antibodies [HAHA]) levels in serum.
HAHA levels
Time frame: Visits Day 1 through Day 180
AV-380 immunogenicity in healthy subjects - Monocyte chemoattractant protein 1 (MCP-1) levels in serum.
Serum MCP-1 levels will be measured.
Time frame: Visits Day 1 and Day 2
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2021 to primary completion in Jan 2022, 10 months.
Of 21 phase 1 interventional studies under Cachexia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 10 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rilogrotug